ALK and non-small cell lung carcinoma: Here, we explored the impact of ICIs on treatment patterns and survival outcomes for patients with locally advanced or metastatic NSCLC without known EGFR mutations/ALK rearrangements treated at Frankfurt University Hospital before and after the first reimbursements for ICIs for advanced NSCLC in Germany.